SciBase

SciBase is a Swedish medical technology company based in Stockholm, focusing on dermatological advancements. With over 20 years of research from the Karolinska Institute, SciBase has developed a unique point-of-care platform that combines artificial intelligence with Electrical Impedance Spectroscopy (EIS) technology. This innovative approach allows for non-invasive detection of skin cancer and assessment of various skin conditions, providing dermatologists and healthcare professionals with objective data to support clinical decision-making. The company's flagship product, Nevisense, is a diagnostic device specifically designed for the early detection of malignant melanoma, the most serious form of skin cancer. Nevisense is the only FDA-approved device for melanoma detection in the United States and has received regulatory approvals in Europe and Australia. In addition to melanoma detection, Nevisense can assess skin barrier function and inflammation, enhancing its clinical applications. SciBase also offers Nevisense Go, which improves accessibility and usability in clinical settings, along with tools for evaluating skin conditions like atopic dermatitis. The company collaborates with major dermatology networks to advance patient care through earlier and more accurate skin cancer detection.

• Employees 32
• Founded 1998
• Annual Revenue $3429000